Chronic Lymphocytic Leukemia

Anthony Mato, MD, Director of the Center for CLL at Penn Medicine, explores the paradigm shift in the front-line treatment of chronic lymphocytic leukemia from chemoimmunotherapy to the kinase inhibitors (KIs), and discusses the KIs as the backbone for the development of new combination regimens. He then offers an overview of new developments in the kinase inhibitor therapies for chronic lymphocytic leukemia and relapsed/refractory disease and the innovation of novel combinations of these agents, including the oral P13KS inhibitor TGR-1202 and the bruton tyrosine kinase inhibitor ACP-196.